Menu
Search
|

Menu

Close
X

Genocea Biosciences Inc GNCA.OQ (NASDAQ Stock Exchange Global Market)

1.00 USD
+0.02 (+2.02%)
As of Feb 16
chart
Previous Close 0.98
Open 0.99
Volume 66,597
3m Avg Volume 168,360
Today’s High 1.01
Today’s Low 0.96
52 Week High 7.28
52 Week Low 0.79
Shares Outstanding (mil) 28.67
Market Capitalization (mil) 50.18
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
1
EPS (USD)
FY17
-1.983
FY16
-1.751
FY15
-1.802
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
2.61
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
89.62
16.52
LT Debt to Equity (MRQ)
vs sector
56.20
12.22
Return on Investment (TTM)
vs sector
-97.45
14.43
Return on Equity (TTM)
vs sector
-127.17
16.13

EXECUTIVE LEADERSHIP

Katrine Bosley
Chairman of the Board, Since 2013
Salary: --
Bonus: --
William Clark
President, Chief Executive Officer, Director, Since 2011
Salary: $427,392.00
Bonus: --
Jonathan Poole
Chief Financial Officer, Since 2015
Salary: $328,000.00
Bonus: --
John Bishop
Executive Vice President - Pharmaceutical Sciences, Since 2016
Salary: --
Bonus: --
Jessica Flechtner
Chief Scientific Officer, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

100 Acorn Park Dr
CAMBRIDGE   MA   02140-2303

Phone: +1617.8768191

Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual's tumor.

SPONSORED STORIES